New York Medicaid spending on GLP-1 drugs

How much did New York Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $941.2 million for GLP-1 drugs paid through New York Medicaid in 2025, across at least 816,616 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 67 rows of 245, so these figures are floors.

Pharmacies were reimbursed at least $255.7 million for GLP-1 drugs paid through New York Medicaid in 2026 (quarter 1 only, as posted so far), across at least 217,802 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 16 rows of 58, so these figures are floors.

By year and ingredient

2020at least $43,837,074No dataat least $48,101,895at least $101,131,701at least $7,328,353at least $68,804$732,732$372,169at least $201,572,728
2021at least $103,160,759No dataat least $29,816,326at least $164,134,102at least $7,501,205at least $25,517$794,177at least $252,527at least $305,684,613
2022at least $190,908,943at least $950,400at least $20,612,556at least $214,144,081at least $8,326,945at least $7,495$684,590at least $167,024at least $435,802,034
2023at least $392,497,992at least $41,712,405at least $17,125,408at least $238,290,350at least $5,880,899Suppressedat least $759,631at least $125,119at least $696,391,804
2024at least $512,221,186at least $120,316,788at least $6,323,291at least $166,081,480at least $1,750,825No dataat least $686,040$167,514at least $807,547,124
2025at least $579,192,050at least $237,153,466at least $2,545,035at least $121,252,556at least $281,018No dataat least $603,792$159,169at least $941,187,086
2026 (Q1)at least $146,802,313at least $83,309,385$471,455at least $25,015,458No dataNo data$109,868$33,518at least $255,741,996

By product, 2025

Ozempicat least $545,985,976at least 464,3716 of 34
Rybelsusat least $32,940,410at least 24,2527 of 25
Wegovyat least $265,664at least 19714 of 19
Mounjaroat least $237,116,161at least 218,8644 of 48
Zepboundat least $37,305at least 118 of 9
Liraglutide (generic name listing)at least $1,909,600at least 3,3919 of 29
Victoza$635,4358160 of 8
Trulicityat least $121,252,556at least 103,6725 of 49
Bydureonat least $281,018at least 3084 of 6
ByettaSuppressedSuppressed3 of 3
Exenatide (generic name listing)SuppressedSuppressed4 of 4
Soliquaat least $603,792at least 6163 of 7
Xultophy$159,1691180 of 4

By quarter, 2025

Q1 2025at least $223,239,059at least 193,87915 of 59
Q2 2025at least $232,671,785at least 202,04216 of 60
Q3 2025at least $240,650,366at least 208,42913 of 59
Q4 2025at least $244,625,876at least 212,26623 of 67

By quarter, 2026 (posted so far)

Q1 2026at least $255,741,996at least 217,80216 of 58

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.